CloneID: 146B7 (Ordesekimab; AMG-714)
Antigen Long Description: The original antibody was generated by immunizing human immunoglobulin transgenic mice strain HCo12 and HCo7 mice with recombinant human IL-15.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P40933
Specificity Statement: This antibody binds human IL-15. It was reported that the epitope this antibody recognizes is involved in interaction with the IL-15R γ-chain. Interleukin 15 (IL-15), also known as MGC9721, is a 14 to 15 kD pro-inflammatory cytokine which is expressed in multiple tissues (placenta, skeletal muscle, kidney, lung, heart, monocytes/macrophages) and numerous cell types including monocytes and macrophages, blood derived dendritic cells, epithelial and fibroblast cells, through various stimulatory conditions. Interleukin-15 regulates T and natural killer (NK) cell activation, survival and proliferation. This cytokine and interleukin 2 (IL-2) share many biological activities, consistent with their shared receptor signaling components (IL-2/15Rβ and IL-2/15Ryc).
Application Notes (Clone): This antibody did not compete with IL-15 for binding to its receptor but potently interfered with the assembly of the IL-15 receptor alpha, beta, gamma complex. This antibody could bind recombinant human IL-15 in an ELISA. In vitro, this antibody effectively blocked IL-15-induced T cell proliferation and monocyte TNF-alpha release. In a human psoriasis xenograft model, antibody 146B7 reduced the severity of psoriasis, as measured by epidermal thickness, grade of parakeratosis, and numbers of inflammatory cells and cycling keratinocytes (PMID: 14617758). IL-15 is implicated in coeliac disease. A randomized, double-blind, placebo-controlled, parallel-group, phase 2a trial was done at three clinical sites in Finland to investigate the effects of AMG 714 in patients with coeliac disease who underwent gluten challenge (PMID: 31494096). The binding of this antibody to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain (PMID: 36083248). Upon administration, ordesekimab binds to and neutralizes IL-15, thereby preventing IL-15-mediated pro-inflammatory signaling. By inhibiting IL-15-mediated immune responses, ordesekimab decreases natural killer (NK) cell activation and proliferation, reduces T-cell infiltration, increases T-cell apoptosis, and may prevent the growth of IL-15-driven cancer cells (National Cancer Institute, NCI Drug Dictionary).
Deutsch
English
